Adare Pharma Solutions, in collaboration with Laxxon Medical, offers clinical scale cGMP 3D screen printing capabilities from our Pessano facility in Milan, Italy. This innovative technology empowers a wide range of enhanced dose flexibility capabilities.

• Customized medicines
• Multi-drug medications
• Reduction of daily pills
• Tailored drug release
• Combine IR, ER, and DR
• Standard excipients
• 505(b)2 extension
• Longer IP protection

Laxxon Medical’s proprietary Screen-Printed Innovative Drug (SPID®) Technology is a cold-process
3D screen printing platform that unlocks technical and clinical advancements for a wide range of
pharmaceutical therapies. Materials are combined into a semi-solid paste, which is then applied in layers
ranging from 10 μm to 150 μm to produce tablets.

3D screen printing allows for the formulation of complex pharmaceuticals with optimized properties, including freely customizable release profiles of one or more APIs, improved bioavailability, shape modifications for ease of swallowing, and tailored pharmacokinetics.

3D Screen Printing is offered from our Pessano facility in Milan, Italy. This flexible cGMP suite permits direct scaling from laboratory quantities through to clinical trial material volumes. Commercial scale equipment will be added at a later date.

To learn more about our 3D Screen Printing capabilities, contact us today to speak with our drug delivery experts.